Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Phase 3 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Chronic Hcv ◽

High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

10.1055/s-0039-1695339 ◽

2019 ◽

Author(s):

S Christensen ◽

A Stoehr ◽

M Cornberg ◽

H Klinker ◽

R Heyne ◽

...

Keyword(s):

Hepatitis C ◽

Real World ◽

Genotype 1 ◽

Substitution Therapy ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

International Journal of Drug Policy ◽

10.1016/j.drugpo.2018.10.004 ◽

2018 ◽

Vol 62 ◽

pp. 94-103 ◽

Cited By ~ 12

Author(s):

Jason Grebely ◽

Brian Conway ◽

Evan B. Cunningham ◽

Chris Fraser ◽

Alberto Moriggia ◽

...

Keyword(s):

Drug Use ◽

Injecting Drug Use ◽

Genotype 1 ◽

Substitution Therapy ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

THU-125-High real-world effectiveness of elbasvir/grazoprevir in PWID on opioid substitution therapy with HCV genotype 1 infection: Results from the German hepatitis C registry (DHC-R)

10.1016/s0618-8278(19)30400-1 ◽

2019 ◽

Vol 70 (1) ◽

pp. e214

Author(s):

Stefan Christensen ◽

Albrecht Stoehr ◽

Markus Cornberg ◽

Hartwig Klinker ◽

Renate Heyne ◽

...

Keyword(s):

Hepatitis C ◽

Real World ◽

Genotype 1 ◽

Substitution Therapy ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

10.1016/s0168-8278(15)30158-6 ◽

2015 ◽

Vol 62 ◽

pp. S264-S265 ◽

Cited By ~ 45

Author(s):

E. Lawitz ◽

G. Matusow ◽

E. DeJesus ◽

E. Yoshida ◽

F. Felizarta ◽

...

Keyword(s):

Efficacy And Safety ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

10.1016/s0168-8278(15)30168-9 ◽

2015 ◽

Vol 62 ◽

pp. S270 ◽

Cited By ~ 44

Author(s):

P. Kwo ◽

N. Gitlin ◽

R. Nahass ◽

D. Bernstein ◽

S. Rojter ◽

...

Keyword(s):

Efficacy And Safety ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Hcv Genotype ◽

Treatment Naïve ◽

Hcv Genotype 1 ◽

Final SVR24 Data From the Phase 3 C-Edge Treatment-Naïve Study of Elbasvir (EBR)/Grazoprevir (GZR) in Patients with Chronic HCV Genotype 1, 4 or 6 Infection

10.1016/s0168-8278(16)01606-8 ◽

2016 ◽

Vol 64 (2) ◽

pp. S821 ◽

Cited By ~ 1

Author(s):

S. Zeuzem ◽

R. Ghalib ◽

K.R. Reddy ◽

P. Pockros ◽

Z.B. Ari ◽

...

Keyword(s):

Genotype 1 ◽

Phase 3 ◽

Hcv Genotype ◽

Treatment Naïve ◽

Edge Treatment ◽

Hcv Genotype 1 ◽

721 - Efficacy and Safety of Glecaprevir/Pibrentasvir in Renallyimpaired Patients with Chronic HCV Genotype 1-6 Infection

Gastroenterology ◽

10.1016/s0016-5085(18)33673-4 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-1104-S-1105

Author(s):

Eric Lawitz ◽

Robert Flisiak ◽

Manal Abunimeh ◽

Meghan Sise ◽

Jun Yong Park ◽

...

Keyword(s):

Efficacy And Safety ◽

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Clinical Infectious Diseases ◽

10.1093/cid/ciw579 ◽

2016 ◽

Vol 63 (11) ◽

pp. 1479-1481 ◽

Cited By ~ 66

Author(s):

Jason Grebely ◽

Gregory J. Dore ◽

Stefan Zeuzem ◽

Richard J. Aspinall ◽

Raymond Fox ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Efficacy And Safety ◽

Hepatitis C Virus Infection ◽

Substitution Therapy ◽

Phase 3 ◽

Chronic Hepatitis C Virus ◽

Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life

Zeitschrift für Gastroenterologie ◽

10.1055/s-0035-1567991 ◽

2015 ◽

Vol 53 (12) ◽

Author(s):

P Buggisch ◽

H Löhr ◽

G Teuber ◽

H Steffens ◽

M Kraus ◽

...

Keyword(s):

Triple Therapy ◽

Real Life ◽

Efficacy And Safety ◽

Genotype 1 ◽

Hcv Genotype ◽

Previously Treated Patients ◽

Previously Treated ◽

Hcv Genotype 1

Faculty Opinions recommendation of Boceprevir for untreated chronic HCV genotype 1 infection.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13863968.15301070 ◽

2012 ◽

Author(s):

Jean-Michel Pawlotsky

Keyword(s):

Genotype 1 ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽